Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    CAS-97519-39-6

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,364Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Basilea Secures BARDA Contract For Ceftibuten-Ledaborbactam
    Basilea Secures BARDA Contract For Ceftibuten-Ledaborbactam

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3155972/0/en/Basilea-awarded-BARDA-contract-for-the-development-of-novel-oral-phase-3-ready-antibiotic-ceftibuten-ledaborbactam.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    Basilea In-Licenses Novel Oral Antibiotic for Clinical Phase 3
    Basilea In-Licenses Novel Oral Antibiotic for Clinical Phase 3

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133159/0/en/Basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share